Cargando…

Frontiers and Opportunities: Highlights of the 2(nd) Annual Conference of the Chinese Antibody Society

The Chinese Antibody Society (CAS) convened the second annual conference in Cambridge, MA, USA on 29 April 2018. More than 600 members from around the world attended the meeting. Invited speakers discussed the latest advancements in therapeutic antibodies with an emphasis on the progress made in Chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hongyu, Deng, Mi, Lin, Peng, Liu, Junjian, Liu, Cheng, Strohl, William R, Wang, Shouye, Ho, Mitchell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206438/
http://dx.doi.org/10.1093/abt/tby009
_version_ 1783366361239519232
author Zhang, Hongyu
Deng, Mi
Lin, Peng
Liu, Junjian
Liu, Cheng
Strohl, William R
Wang, Shouye
Ho, Mitchell
author_facet Zhang, Hongyu
Deng, Mi
Lin, Peng
Liu, Junjian
Liu, Cheng
Strohl, William R
Wang, Shouye
Ho, Mitchell
author_sort Zhang, Hongyu
collection PubMed
description The Chinese Antibody Society (CAS) convened the second annual conference in Cambridge, MA, USA on 29 April 2018. More than 600 members from around the world attended the meeting. Invited speakers discussed the latest advancements in therapeutic antibodies with an emphasis on the progress made in China. The meeting covered a vast variety of topics including the current status of therapeutic antibodies, the progress of immuno-oncology, and biosimilars in China. The conference presentations also included the development of several novel antibodies such as antibodies related to weight loss, T-cell receptor-mimicking antibodies that target intracellular antigens, and tumor-targeting antibodies that utilize both innate and adaptive immune pathways. At the meeting, the CAS announced the launch of its official journal—Antibody Therapeutics—in collaboration with Oxford University Press. The conference was concluded by a panel discussion on how to bring a therapeutic drug developed in China to the USA for clinical trials.
format Online
Article
Text
id pubmed-6206438
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62064382018-11-05 Frontiers and Opportunities: Highlights of the 2(nd) Annual Conference of the Chinese Antibody Society Zhang, Hongyu Deng, Mi Lin, Peng Liu, Junjian Liu, Cheng Strohl, William R Wang, Shouye Ho, Mitchell Antib Ther Meeting Reports The Chinese Antibody Society (CAS) convened the second annual conference in Cambridge, MA, USA on 29 April 2018. More than 600 members from around the world attended the meeting. Invited speakers discussed the latest advancements in therapeutic antibodies with an emphasis on the progress made in China. The meeting covered a vast variety of topics including the current status of therapeutic antibodies, the progress of immuno-oncology, and biosimilars in China. The conference presentations also included the development of several novel antibodies such as antibodies related to weight loss, T-cell receptor-mimicking antibodies that target intracellular antigens, and tumor-targeting antibodies that utilize both innate and adaptive immune pathways. At the meeting, the CAS announced the launch of its official journal—Antibody Therapeutics—in collaboration with Oxford University Press. The conference was concluded by a panel discussion on how to bring a therapeutic drug developed in China to the USA for clinical trials. Oxford University Press 2018-10-11 /pmc/articles/PMC6206438/ http://dx.doi.org/10.1093/abt/tby009 Text en © The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Meeting Reports
Zhang, Hongyu
Deng, Mi
Lin, Peng
Liu, Junjian
Liu, Cheng
Strohl, William R
Wang, Shouye
Ho, Mitchell
Frontiers and Opportunities: Highlights of the 2(nd) Annual Conference of the Chinese Antibody Society
title Frontiers and Opportunities: Highlights of the 2(nd) Annual Conference of the Chinese Antibody Society
title_full Frontiers and Opportunities: Highlights of the 2(nd) Annual Conference of the Chinese Antibody Society
title_fullStr Frontiers and Opportunities: Highlights of the 2(nd) Annual Conference of the Chinese Antibody Society
title_full_unstemmed Frontiers and Opportunities: Highlights of the 2(nd) Annual Conference of the Chinese Antibody Society
title_short Frontiers and Opportunities: Highlights of the 2(nd) Annual Conference of the Chinese Antibody Society
title_sort frontiers and opportunities: highlights of the 2(nd) annual conference of the chinese antibody society
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206438/
http://dx.doi.org/10.1093/abt/tby009
work_keys_str_mv AT zhanghongyu frontiersandopportunitieshighlightsofthe2ndannualconferenceofthechineseantibodysociety
AT dengmi frontiersandopportunitieshighlightsofthe2ndannualconferenceofthechineseantibodysociety
AT linpeng frontiersandopportunitieshighlightsofthe2ndannualconferenceofthechineseantibodysociety
AT liujunjian frontiersandopportunitieshighlightsofthe2ndannualconferenceofthechineseantibodysociety
AT liucheng frontiersandopportunitieshighlightsofthe2ndannualconferenceofthechineseantibodysociety
AT strohlwilliamr frontiersandopportunitieshighlightsofthe2ndannualconferenceofthechineseantibodysociety
AT wangshouye frontiersandopportunitieshighlightsofthe2ndannualconferenceofthechineseantibodysociety
AT homitchell frontiersandopportunitieshighlightsofthe2ndannualconferenceofthechineseantibodysociety